Galecto

Galecto is a clinical-stage biotechnology company that specializes in developing small molecules aimed at treating severe diseases, particularly fibrosis and cancer. Founded in 2011, the company focuses on two main therapeutic targets: galectin-3 and lysyl oxidase-like 2 (LOXL2). Its lead product candidate, GB0139, is an inhaled inhibitor of galectin-3, specifically designed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), which presents a significant unmet medical need. In addition to GB0139, Galecto is also advancing GB1211, a selective oral galectin-3 inhibitor intended for addressing fibrosis associated with non-alcoholic steatohepatitis. The company's innovative research, supported by a strong patent portfolio, positions it uniquely within the biotechnology landscape, targeting the underlying biological processes of fibrosis and related diseases.